BIONIK LABORATORIES CORP. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2018-12-19: Form 8-K; Period of report 2018-12-18; Description 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; Details 1.01.
- 2018-12-17: Form 8-K; Period of report 2018-12-14; Description 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; Details 1.01.
- 2018-11-13: Form 8-K; Period of report 2018-11-13; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2018-11-06: Form 8-K; Period of report 2018-10-31; Description 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2018-12-19 | 8-K | 2018-12-18 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 The information set forth in Item 2.03 is incorporated by reference into this Item 1.01. 2.03 On December 18, 2018, an existing investor (the “Lender”) of Bionik Laboratories Corp. (the “Company”) loaned to the Company an aggregate of $400,000 (the “Loan”), evidenced by a convertible promissory note (the “Note”). 3.02 The disclosure set forth above in Item 2.03 of this Current Report on Form 8-K relating to the issuance of the Note is incorporated by reference herein. | tv509538_8-k.htm |
| 2018-12-17 | 8-K | 2018-12-14 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry Into A Material definitive Agreement. 8.01 The Company issued a press release on December 17, 2018 in connection with the Agreement. | tv509222_8k.htm |
| 2018-11-13 | 8-K | 2018-11-13 | 2.02 Results of Operations and Financial Condition | 2.02 On November 13, 2018, Bionik Laboratories Corp. issued a press release announcing its financial results for the fiscal quarter ended September 30, 2018. | tv507061_8-k.htm |
| 2018-11-06 | 8-K | 2018-10-31 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 The information set forth in Item 2.03 is incorporated by reference into this Item 1.01. 2.03 On October 31, 2018, a new investor (the “Lender”) of Bionik Laboratories Corp. (the “Company”) subscribed for a convertible promissory note (the “Note”) and loaned to the Company an aggregate of $450,000 (the “Loan”). 3.02 The disclosure set forth above in Item 2.03 of this Current Report on Form 8-K relating to the issuance of the Note is incorporated by reference herein. | tv506402_8k.htm |
| 2018-10-30 | 8-K | 2018-10-30 | 7.01 Regulation FD Disclosure | 7.01 On October 30, 2018, Bionik Laboratories Corp. issued a press release announcing the filing of a Registration Statement on Form S-1 (File No. 333-228044) with the U.S. Securities and Exchange Commission. | tv505818_8k.htm |
| 2018-10-29 | 8-K | 2018-10-26 | 3.03 Material Modification to Rights of Security Holders; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 8.01 Other Events | 3.03 The information set forth in Item 5.03 is incorporated by reference into this Item 3.03. 5.03 On October 26, 2018, as approved by a majority of the stockholders of Bionik Laboratories Corp. (the “Company”) by written consent in lieu of a meeting on or about August 7, 2018, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a one-for-one hundred fifty reverse stock split of the Company’s common stock (the “Reverse Split”), effective as of 4:30 P.M. on October 29, 2018 (the “Certificate of Amendment”). 8.01 The Company issued a press release on October 29, 2018 announcing the Reverse Split. | tv505745_8k.htm |
| 2018-10-24 | 8-K | 2018-10-22 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 8.01 On October 24, 2018, the Company issued a press release announcing that it has entered into a purchase order with Clinique Les Trois Soleils in Boissise-le-Roi, France for the Company’s InMotion Arm™ robot, and that the Company recently received a “CE marking” from the European Commission. | tv505366_8k.htm |
| 2018-10-12 | 8-K | 2018-10-10 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 The information set forth in Item 2.03 is incorporated by reference into this Item 1.01. 2.03 On October 10, 2018, new and existing investors (the “Lenders”) of Bionik Laboratories Corp. (the “Company”) subscribed for convertible promissory notes in substantially the form attached hereto as Exhibit 10.2 (the “Notes”) and loaned to the Company an aggregate of $2,300,000 (the “Loans”). 3.02 The disclosure set forth above in Item 2.03 of this Current Report on Form 8-K relating to the issuance of the Notes is incorporated by reference herein. | tv504737_8k.htm |
| 2018-09-13 | 8-K | 2018-09-07 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 Effective as of September 7, 2018, Michal Prywata, a member of the Board of Directors (the “Board”) of Bionik Laboratories Corp. (the “Company”), and the Company’s Chief Technology Officer, resigned from the Board. 8.01 The Company issued a press release on September 13, 2018 announcing the resignation of Mr. Prywata from the Board and the appointments of Dr. Thevenon and Mr. Matine to the Board. | tv502773_8k.htm |
| 2018-08-14 | 8-K | 2018-08-14 | 2.02 Results of Operations and Financial Condition | 2.02 On August 14, 2018, Bionik Laboratories Corp. issued a press release announcing its financial results for the fiscal quarter ended June 30, 2018. | tv500886_8k.htm |
| 2018-08-10 | 8-K | 2018-08-07 | 5.07 Submission of Matters to a Vote of Security Holders | tv500717_8k.htm | |
| 2018-08-07 | 8-K | 2018-08-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On August 1, 2018, Marc Mathieu, a member of the Board of Directors (the “Board”) of Bionik Laboratories Corp. (the “Registrant”), resigned from his position and roles as a member of the Board. | tv500382_8k.htm |
| 2018-07-26 | 8-K | 2018-07-20 | 3.02 Unregistered Sales of Equity Securities | 3.02 As previously disclosed by Bionik Laboratories Corp. (the “Company”) in its Current Report on Form 8-K, filed with Securities and Exchange Commission on July 20, 2018, new and existing investors (the “Investors”) in the Company subscribed for convertible promissory notes (collectively, the “Notes”) and loaned to the Company an aggregate of $4,708,306 (the “Loans”) pursuant to the Company’s up to $6,000,000 convertible note offering (the “Offering”). | tv499416_8k.htm |
| 2018-07-20 | 8-K | 2018-07-16 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 The information set forth in Item 2.03 is incorporated by reference into this Item 1.01. 2.03 Between July 16, 2018 and July 20, 2018, new and existing investors (the “Lenders”) of Bionik Laboratories Corp. (the “Company”) subscribed for convertible promissory notes (collectively, the “Notes”) and loaned to the Company an aggregate of $1,662,082 (the “Loans”). 3.02 The disclosure set forth above in Item 2.03 of this Current Report on Form 8-K relating to the issuance of the Notes is incorporated by reference herein. | tv498923_8k.htm |
| 2018-07-13 | 8-K | 2018-07-09 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 The information set forth in Item 2.03 is incorporated by reference into this Item 1.01. 2.03 Between July 9, 2018 and July 13, 2018, existing investors (the “Lenders”) of Bionik Laboratories Corp. (the “Company”) subscribed for convertible promissory notes (collectively, the “Notes”) and loaned to the Company an aggregate of $80,253 (the “Loans”). 3.02 The disclosure set forth above in Item 2.03 of this Current Report on Form 8-K relating to the issuance of the Notes is incorporated by reference herein. | tv498537_8k.htm |
| 2018-07-05 | 8-K/A | 2018-06-22 | 1.01 Entry into a Material Definitive Agreement | 1.01 The information set forth in Item 2.03 of the Original 8-K is incorporated by reference into this Item 1.01. | tv498109_8ka.htm |
| 2018-07-05 | 8-K | 2018-06-28 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 The information set forth in Item 2.03 is incorporated by reference into this Item 1.01. 2.03 As previously reported by Bionik Laboratories Corp. (the “Company”) in its Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 28, 2018 (the “Previous 8-K”), existing investors of the Company loaned to the Company an aggregate of $668,928 (the “Original Loans”), representing the first tranche borrowed pursuant to a newly launched up to $6,000,000 convertible note offering (the “Offering”). 3.02 The disclosure set forth above in Item 2.03 of this Current Report on Form 8-K relating to the issuance of the Notes is incorporated by reference herein. | tv498053_8k.htm |
| 2018-06-28 | 8-K | 2018-06-22 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 The information set forth in Item 2.03 is incorporated by reference into this Item 1.01. 2.03 On June 22, 2018, an affiliate of Remi Gaston Dreyfus (the “Affiliate”), a director of Bionik Laboratories Corp. (the “Company”), loaned $160,000 to the Company (the “$160K Loan”), evidenced by a promissory note (the “$160K Note”). 3.02 The disclosure set forth above in Item 2.03 of this Current Report on Form 8-K relating to the issuance of the Loans is incorporated by reference herein. | tv497526_8k.htm |
| 2018-06-27 | 8-K | 2018-06-27 | 2.02 Results of Operations and Financial Condition | 2.02 On June 27, 2018, Bionik Laboratories Corp. issued a press release announcing its financial results for the fiscal year ended March 31, 2018. | tv497357_8k.htm |
| 2018-06-21 | 8-K | 2018-06-21 | 7.01 Regulation FD Disclosure | 7.01 On June 21, 2018, Bionik Laboratories Corp. issued a press release announcing that it has delivered two of its InMotion Arm robotic systems to The Transitional Learning Center. | tv496930_8k.htm |
| 2018-06-13 | 8-K | 2018-06-11 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 1.01 The information set forth in Item 2.03 is incorporated by reference into this Item 1.01. 2.03 On June 12, 2018, an affiliate of Remi Gaston Dreyfus (the “Lender”), a director of Bionik Laboratories Corp. (the “Company”), loaned $100,000 to the Company (the “Loan”), evidenced by a promissory note (the “Note”). 3.02 As previously disclosed by the Company in its Current Report on Form 8-K, filed with the Securities and Exchange Commission on April 3, 2018, as of March 31, 2018 the Company became obligated to issue an aggregate of 39,545,776 shares of common stock (the “Shares”) as a result of the conversion of certain outstanding convertible promissory notes in accordance with their terms. 5.03 On June 11, 2018, as approved by a majority of the stockholders of the Company by written consent in lieu of a meeting on April 20, 2018, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to increase the number of authorized shares of the Company’s common stock from 250,000,000 shares to 500,000,000 shares (the “Certificate of Amendment”). | tv496447_8k.htm |
| 2018-06-11 | 8-K | 2018-06-11 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 1.01 The information set forth in Item 5.02 in this Form 8-K is incorporated herein by reference. 5.02 On June 11, 2018, Bionik Laboratories Corp. (the “Registrant”) issued a press release publicly announcing the appointment of Renaud Maloberti, age 49, as the Registrant’s new Chief Commercial Officer. | tv496263_8k.htm |
| 2018-06-08 | 8-K | 2018-05-10 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 The information set forth in Item 2.03 is incorporated by reference into this Item 1.01. 2.03 On May 10, 2018, an affiliate of Remi Gaston Dreyfus (the “Lender”), a director of Bionik Laboratories Corp. (the “Company”), loaned $190,000 to the Company (the “Loan”), evidenced by a promissory note (the “Note”). | tv496237_8k.htm |
| 2018-06-08 | 8-K | 2018-04-26 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 The information set forth in Item 2.03 is incorporated by reference into this Item 1.01. 2.03 On April 26, 2018, an affiliate of Remi Gaston Dreyfus (the “Lender”), a director of Bionik Laboratories Corp. (the “Company”), loaned $500,000 to the Company (the “Loan”), evidenced by a promissory note (the “Note”). | tv496239_8k.htm |
| 2018-05-31 | 8-K | 2018-05-24 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 The information set forth in Item 2.03 is incorporated by reference into this Item 1.01. 2.03 On May 24, 2018, an affiliate of Remi Gaston Dreyfus (the “Lender”), a director of Bionik Laboratories Corp. (the “Company”), loaned $590,000 to the Company (the “Loan”), evidenced by a promissory note (the “Note”). | tv495517_8k.htm |
| 2018-05-16 | 8-K | 2018-05-16 | 7.01 Regulation FD Disclosure | 7.01 On May 16, 2018, Bionik Laboratories Corp. (the “Company”), issued a press release announcing that the Company has entered into a rental agreement with Tallahassee Memorial HealthCare in Tallahassee, Florida for the Company’s InMotion Arm robotic system. | tv494297_8k.htm |
| 2018-05-15 | 8-K/A | 2018-04-20 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 On April 20, 2018, Eric Dusseux, the Chief Executive Officer and a director of Bionik Laboratories Corp. (the “Company”), was granted a stock option representing a right to acquire 6,000,000 shares of the Company’s common stock. | tv494256_8ka.htm |
| 2018-04-25 | 8-K | 2018-04-20 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 20, 2018, Eric Dusseux, the Chief Executive Officer and a director of Bionik Laboratories Corp. (the “Company”), was granted a stock option representing a right to acquire 6,000,000 shares of the Company’s common stock. | tv491934_8k.htm |
| 2018-04-18 | 8-K | 2018-04-12 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 1.01 The information set forth in Item 2.03 is incorporated by reference into this Item 1.01. 2.03 On April 12, 2018, an affiliate of Remi Gaston Dreyfus, a director of Bionik Laboratories Corp. (the “Company”) loaned $420,000 to the Company, evidenced by a Promissory Note dated as of April 12, 2018 (the “Note”). 5.02 On April 12, 2018, Tim McCarthy, the Chief Commercialization Officer of Bionik Laboratories Corp. (the “Company”), resigned from his position with the Company, effective April 27, 2018. | tv491341_8k.htm |
| 2018-04-03 | 8-K | 2018-03-29 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 5.01 Changes in Control of Registrant; 8.01 Other Events | 1.01 On March 30, 2018, Bionik Laboratories Corp. (“the Company”) and the holders of a majority in original aggregate principal amount of certain existing promissory notes, in the aggregate principal amount of approximately $5,000,000, issued by the Company to certain investors (the “Investors”) in December 2016 – December 2017 (the “Existing Notes”), agreed to amend the terms of all of the Existing Notes and warrants issued by the Company in relation to the Existing Notes (the “Existing Warrants”). 2.03 On March 29, 2018, investors (the “Lenders”) of the Company subscribed for convertible promissory notes and loaned to the Company an aggregate of approximately $350,000 (the “Loans”). 3.02 The disclosure set forth above in Item 2.03 of this Current Report on Form 8-K relating to the issuance of the 2018 Notes is incorporated by reference herein. 5.01 The information set forth under Item 3.02 of this Current Report on Form 8-K is incorporated into this Item 5.01 by reference. 8.01 The Company issued a press release on April 3, 2018 in connection with the Conversion. | tv490251_8k.htm |
| 2018-03-28 | 8-K | 2018-03-22 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 The information set forth in Item 2.03 is incorporated by reference into this Item 1.01. 2.03 Between March 22, 2018 and March 28, 2018, investors (the “Lenders”) of Bionik Laboratories Corp. (the “Company”) subscribed for convertible promissory notes (the “Notes”) and loaned to the Company an aggregate of approximately $255,000 (the “Loans”). 3.02 The disclosure set forth above in Item 2.03 of this Current Report on Form 8-K relating to the issuance of the Notes is incorporated by reference herein. | tv489787_8k.htm |
| 2018-03-20 | 8-K | 2018-03-14 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 Effective as of March 14, 2018, Peter Bloch, a member of the Board of Directors (the “Board”) of Bionik Laboratories Corp. (the “Company”), resigned from the Board. 8.01 The Company issued a press release on March 20, 2018 announcing the appointments of Messrs. | tv488955_8k.htm |
| 2018-03-14 | 8-K | 2018-03-08 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 1.01 As previously disclosed by Bionik Laboratories Corp. (the “Company”) in its Current Report on Form 8-K, filed with the Securities and Exchange Commission on September 11, 2017, the Company and Peter Bloch, the Company’s former chief executive officer, entered into a separation agreement, dated September 1, 2017 (the “Separation Agreement”). 1.02 The information set forth in Item 2.03 concerning the termination of the Original $500K Note (as defined below) is incorporated by reference into this Item 1.02. 2.03 Between March 8, 2018 and March 14, 2018, an investor (the “Lender”) of the Company, who is an affiliate of Remi Gaston Dreyfus, a director of the Company, subscribed for convertible promissory notes (the “$300K Notes”) and loaned to the Company an aggregate of $300,000 (the “$300K Loans”). 3.02 The disclosure set forth above in Item 2.03 of this Current Report on Form 8-K relating to the issuance of the Notes is incorporated by reference herein. 5.02 The information set forth in Item 1.01 is incorporated by reference into this Item 5.02. | tv488514_8k.htm |
| 2018-03-07 | 8-K | 2018-03-06 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 On March 6, 2018, Bionik Laboratories Corp. (the “Company”), entered into a Distribution Agreement (the “Agreement”) with Curexo Inc. (“Curexo”). 8.01 The Company issued a press release on March 7, 2018 in connection with the Agreement. | tv487931_8k.htm |
| 2018-02-13 | 8-K | 2018-02-09 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 1.01 The information set forth in Item 2.03 is incorporated by reference into this Item 1.01. 2.03 On February 9, 2018, investors (the “Lenders”) of Bionik Laboratories Corp. (the “Company”) subscribed for convertible promissory notes (the “Notes”) and loaned to the Company an aggregate of approximately $296,000 (the “Loans”). 3.02 The disclosure set forth above in Item 2.03 of this Current Report on Form 8-K relating to the issuance of the Notes is incorporated by reference herein. 8.01 On February 13, 2018, the Company issued a press release announcing its financial results for the third quarter ended December 31, 2017. | tv485989_8k.htm |
| 2018-02-05 | 8-K | 2018-01-30 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 8.01 Other Events | 1.01 As previously announced by Bionik Laboratories Corp. (the “Company”), as of January 19, 2018 investors (the “Lenders”) of the Company had subscribed for convertible promissory notes (the “Notes”) and loaned to the Company an aggregate of approximately $1,510,000 pursuant to an up to $14,000,000 convertible note offering. 2.03 On February 2, 2018, an existing investor of the Company, who is an affiliate of Remi Gaston Dreyfus, a director of the Company, loaned $500,000 (the “$500K Loan”) to the Company evidenced by a promissory note, dated February 2, 2018 (the “$500K Note”). 8.01 On February 5, 2018, the Company issued a press release announcing the launch of its improved InMotion Arm interactive robotic system for clinical rehabilitation of stroke survivors and those with mobility impairments due to neurological conditions. | tv484887_8k.htm |
| 2018-01-29 | 8-K | 2018-01-24 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 Effective as of January 24, 2018, Peter Bloch, Chairman of the Board of Directors (the “Board”) of Bionik Laboratories Corp. (the “Company”), resigned as Chairman of the Board. 8.01 The Company issued a press release on January 29, 2018 in connection with the Agreement. | tv484240_8k.htm |
| 2018-01-25 | 8-K | 2018-01-19 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 The information set forth in Item 2.03 is incorporated by reference into this Item 1.01. 2.03 On January 19, 2018, an investor (the “Lender”) of Bionik Laboratories Corp. (the “Company”) subscribed for a convertible promissory note (the “Note”) and loaned to the Company $60,000 (the “Loan”). 3.02 The disclosure set forth above in Item 2.03 of this Current Report on Form 8-K relating to the issuance of the Note is incorporated by reference herein. | tv484060_8k.htm |
| 2018-01-16 | 8-K | 2018-01-09 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 The information set forth in Item 2.03 is incorporated by reference into this Item 1.01. 2.03 Between January 9, 2018 and January 11, 2018, investors (the “Lenders”) of Bionik Laboratories Corp. (the “Company”) subscribed for convertible promissory notes (the “Notes”) and loaned to the Company an aggregate of approximately $200,000 (the “Loans”). 3.02 The disclosure set forth above in Item 2.03 of this Current Report on Form 8-K relating to the issuance of the Notes is incorporated by reference herein. | tv483350_8k.htm |
| 2018-01-04 | 8-K | 2017-12-29 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 The information set forth in Item 2.03 is incorporated by reference into this Item 1.01. 2.03 Between December 29, 2017 and January 3, 2018, investors (the “Lenders”) of Bionik Laboratories Corp. (the “Company”) subscribed for convertible promissory notes (the “Notes”) and loaned to the Company an aggregate of $1,050,000 (the “Loans”). 3.02 The disclosure set forth above in Item 2.03 of this Current Report on Form 8-K relating to the issuance of the Notes is incorporated by reference herein. | tv482736_8k.htm |